



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/511,480

11/15/2005

Henry Nicolas Jabbour

20747/210

6559

Edwin V Merkel  
Nixon Peabody  
Clinton Square  
P O Box 31051  
Rochester, NY 14603

7590

04/28/2009

EXAMINER

SZNAIDMAN, MARCOS L

ART UNIT

PAPER NUMBER

1612

MAIL DATE

DELIVERY MODE

04/28/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/511,480	<b>Applicant(s)</b> JABBOUR ET AL.	
	<b>Examiner</b> MARCOS SZNAIDMAN	<b>Art Unit</b> 1612	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 26 February 2009.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,3-5,9,12,13 and 32 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 3-5, 9, 12-13 and 32 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

This office action is in response to applicant's reply filed on February 26, 2009.

Receipt of Declarations under 37 CFR 1.132 is acknowledged.

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114.

### ***Status of claims***

Addition of new claim 32 is acknowledged.

Claims 1, 3-5, 9, 12-13 and 32 are currently pending and are the subject of this office action.

Claims 1, 3-5, 9, 12-13 and 32 are presently under examination.

### ***Priority***

The present application is a 371 of PCT/GB03/01521 filed on 04/10/2003, which claims priority to foreign application: United Kingdom 0208785.6 filed on 04/17/2002.

***Rejections and/or Objections and Response to Arguments***

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Rejections and/or Objections) or newly applied (New Rejections and/or Objections, Necessitated by Amendment or New Rejections and/or Objections not Necessitated by Amendment). They constitute the complete set presently being applied to the instant application.

***Claim Rejections - 35 USC § 112 (Maintained Rejection)***

Claims 1, 3-5, 9, 12-13 and new claim 32 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement.

The reasons for this rejection have been provided in the previous office action dated January 29, 2008, the text of which is incorporated by reference herein.

Applicant's arguments have been fully considered but are not persuasive.

Applicant arguments are similar to the ones previously presented: in the 1.132 declaration and in its remarks, Applicant argues that the specification provides enough data to overcome the enablement rejection. Specifically, Applicants lists all the mechanistic reasons that support their claim that "FP receptor antagonists can treat a female individual for a pathological condition of the uterus associated with abnormal growth of cells of the myometrium or endometrium, including uterine carcinoma,

Art Unit: 1612

endometriosis and fibroids". These mechanistic reasons are: 1- the discovery for the first time that there is a higher level of expression of the FP receptor in the uterus during the proliferative phase of the endometrium in the menstrual cycle and that expression in uterine carcinoma tissue is significantly elevated compared with normal uterine tissue, 2- there is elevated expression of the FP receptor in pathological conditions of the uterus, 3- In Dr. Jabbour declaration and in the Sales reference (Cancer. Res. (2002) 65:7707-7716) it is shown that elevated FP receptor and VEGF expression are co-localized in glandular and epithelial cells lining the blood vessels in endometrial (uterine) adenocarcinomas, and 4- PGF2alpha (the natural ligand of the FP receptor) can cause rapid transphosphorylation and activation of the EGF receptor, and activation of MEK signaling via the FP receptor, resulting in an increase in VEGF promoter activity, expression of VEGF mRNA and secretion of VEGF protein, all of which are consistent with a role for the FP receptor in stimulating blood vessel formation (angiogenesis) in endometrial (uterine) cancer.

These effects of PGF2alpha on the FP receptor could be abolished by treatment of cells with specific FP receptor antagonist, AL8810, and similar effects were found when endometrial adenocarcinoma explants were treated with AL8810.

Examiner's response: all the above arguments only prove that the FP receptor might play a role in the diseases of the uterus claimed by applicant (uterine cancer, fibroids and endometriosis), and definitively is an invitation for further research in this area. However, these arguments do not demonstrate that an FP receptor antagonist could treat any of these diseases. There is no *in-vitro* or *in-vivo* data and/or proof of

Art Unit: 1612

mechanism in the instant application and in the literature of any kind to suggest that an FP antagonist might be useful in the treatment of uterine cancer, fibroids and endometriosis.

MPEP 2164.03 cites: “the amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The “amount of guidance or direction” refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling. >See, e.g., *Chiron Corp. v. Genentech Inc.*, 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1326 (Fed. Cir. 2004) (“Nascent technology, however, must be enabled with a specific and useful teaching.’ The law requires an enabling disclosure for nascent technology because a person of ordinary skill in the art has little or no knowledge independent from the patentee’s instruction. Thus, the public’s end of the bargain struck by the patent system is a full enabling disclosure of the claimed technology.” In the instant case there is nothing in the prior art suggesting that FP antagonists have any effect on treating a pathological condition of the uterus like uterine carcinoma, endometriosis or fibroids. While it is understood that the absence of working examples should never be the sole

Art Unit: 1612

reason for rejecting a claims as being broader than an enabling disclosure, the criticality of working examples in an unpredictable art, such as the treatment of a pathological condition of the uterus like uterine carcinoma, endometriosis or fibroids, is required for practice of the claimed invention. Applicant did not provide a single cell assay that shows that any FP antagonist could prevent or ameliorate the proliferation of a cancerigenous cell. Applicant has provided mechanistic data, that although scientifically relevant, it is not sufficient, for patentability purposes, to establish a correlation with the anticancer activity of FP antagonists. Cancer is a very complex disease that involves several mechanisms, and although one mechanism might have more preponderance over the other, the literature is full of examples of mechanistic approaches that seemed “reasonable and promising” but ultimately failed to prove any utility in fighting any type of cancer. Although the USPTO does not require the same level of data as the FDA, as discussed above, there is a minimum of data that applicant has to provide in order to enable the invention, and the data required is inversely related to the amount of knowledge in the state of the art as well as the predictability of the art. In this case the amount of knowledge is low and the unpredictability is very high.

As mentioned before, the data provided by Applicant in the specification and the 1.132 declaration, although of scientific relevance, it is an invitation for further research in this area.

With the high level of uncertainty in the area of cancer treatment in general, and since neither the prior art nor the instant application provides any relevant data (except for the mechanistic aspects discussed above) that will suggest that FP antagonist can

Art Unit: 1612

treat a pathological condition of the uterus like uterine carcinoma, endometriosis or fibroids, the skilled in the art will have to engage in undue experimentation in order to use the present invention.

Finally, new claim 32 does not solve any of the above issues. Claim 32 introduces new mechanistic aspect of the FP antagonists that do not cure the above discussed deficiencies.

### ***Conclusion***

No claims are allowed.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any



Art Unit: 1612

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

### ***Correspondence***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached on Monday through Thursday 8 AM to 6 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick F. Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1612

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/MARCOS SZNAIDMAN/  
Examiner, Art Unit 1612  
April 20, 2009.

/Frederick Krass/

Supervisory Patent Examiner, Art Unit 1612